Metropolis Healthcare Q1 FY27 Results Analysis: PAT Surges 26%, Cost Ratio Improves 113 bps
Metropolis Healthcare Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 450.21 Cr (+16.62% YoY) and PAT growth of +25.76% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 04, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 450.21 Cr (+16.62% YoY) |
| PAT (Q1) | Rs. 56.67 Cr (+25.76% YoY) |
| EBITDA margin | 25.83% (+63 bps YoY) |
| EPS (Q1) | Rs. 2.73 (+25.81% YoY) |
| Market cap | Rs. 12,120.59 Cr |
| CMP | Rs. 584.50 |
Quarter Snapshot
Revenue grew 16.6% YoY and PAT grew 25.8%, with EBITDA margin of 25.8% within the company's target range. Cost management was excellent, led by a 113 bps improvement in cost of materials ratio. However, subsidiary contributions declined and no explicit full-year guidance was provided, limiting near-term catalysts.
Key Investment Insights
Key Positives
- Revenue grew 16.62% YoY to Rs.450.21 crore
- PAT (attributable to owners) grew 25.76% YoY to Rs.56.67 crore
- EBITDA margin expanded 63 bps YoY to 25.83%, within the 25-26% target range
- Cost of materials ratio improved 113 bps YoY to 19.35%
- EBITDA grew 19.56% YoY, outpacing revenue growth and demonstrating operating leverage
Risk Factors
- Other income fell 32.12% YoY to Rs.5.10 crore, reducing total income growth
- Subsidiary contribution to PAT declined from Rs.9.70 crore in Q1FY26 to Rs.6.01 crore in Q1FY27, indicating thin margins at acquired entities
- Finance costs rose 18.88% YoY to Rs.6.18 crore, tracking an expanded revenue base
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.